Finasteride boosts PSA ability to detect prostate cancer
August 22, 2006
The medication finasteride, which after the seven-year Prostate Cancer Prevention Trial (PCPT) was associated with a 24.8 percent reduction of prostate cancer risk among men who took it, has a new feather in its cap – it beefs up the diagnostic power of the prostate-specific antigen (PSA) test.